Previous 10 | Next 10 |
NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host ...
NEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased the securities of Rain Oncology ...
2023-07-07 08:29:03 ET Prestige Wealth ( PWM ) +106% . Gorilla Technology Group ( GRRR ) +74% Signs Contract to Deploy Massive Smart Government Project in Egypt. NuZee ( NUZE ) +51% Secures Five-Year Global Licensing Deal with Stone Brewing to...
2023-06-05 09:45:25 ET Palm Beach, FL – June 5, 2023 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has had a limited impact on the global breast cancer therapeutics market and reports see substantial growth now that it has receded. The sta...
2023-06-02 08:33:10 ET U Power ( UCAR ) +70% . Connect Biopharma Holdings ( CNTB ) +53% Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis. ...
2023-05-30 11:02:01 ET Rain Oncology ( NASDAQ: RAIN ) shed ~9% in the morning hours Tuesday after announcing layoffs, the departure of the company’s chief medical officer, and changes to its clinical programs for lead candidate milademetan. As part of efforts to strea...
– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial – – Evaluation of outcomes from the MANTRA Phase 3 milademetan trial in dedifferentiated liposarcoma (DD L...
2023-05-23 09:17:14 ET Rain Oncology ( NASDAQ: RAIN ) continued to fall in the pre-market Tuesday after multiple analysts downgraded the company on its decision to halt studies for its lead asset, milademetan in liposarcoma, following a Phase 3 setback. RAIN fell ~88% on Monday ...
2023-05-22 15:15:00 ET Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated liposarcoma, a type of cancer affecting fatty tissue, usually in t...
2023-05-22 10:03:29 ET Gainers: Microbot Medical ( MBOT ) +46% . Hepion Pharmaceuticals ( HEPA ) +41% . Atea Pharmaceuticals ( AVIR ) +38% . VectivBio Holding ( VECT ) +37% . CNS Pharmaceuticals ( CNSP ) +23% . Losers: Rain Oncology ( ...
News, Short Squeeze, Breakout and More Instantly...
Rain Therapeutics Inc. Company Name:
RAIN Stock Symbol:
NASDAQ Market:
Rain Therapeutics Inc. Website:
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire ...
NEW YORK, NY / ACCESSWIRE / January 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Eagle Bulk Shipping Inc. (NYSE:EGLE...